CTOs on the Move

Promega Corporation

www.promega.com

 
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 1,450 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis,
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.promega.com
  • 2800 Woods Hollow Rd
    Madison, WI USA 53711
  • Phone: 608.274.4330

Executives

Name Title Contact Details

Similar Companies

Affigen

Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.

Roar Biomedical

Roar Biomedical is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AdPharma

AdPharma is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inhibitex

Inhibitex, Inc. is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metavention

Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.